Abstract:Abstract BACKGROUND Discovery and verification of protein biomarkers in clinical specimens using mass spectrometry are inherently challenging and resource-intensive. METHODS Formalin-fixed paraffin-embedded tissue-biopsy samples from a prostate cancer patient cohort (PCZA, n = 68) were processed in triplicate using pressure cycling technology, followed by microflow LC SWATH® analysis with different gradients and window schemes. Potential protein biomarker candidates were prioritized using random forest analysis and evaluated by receiver operating characteristic curve analysis. Selected proteins were verified with a targeted MRMHR assay using the 15 min microflow LC strategy on a second prostate cancer cohort (PCZB, n = 54). Potential biomarkers were further verified using TMA on a third cohort (PCZD, n = 100). RESULTS We developed and optimized a 15-min microflow LC approach coupled with microflow SWATH MS. Application of the optimal 15 min and conventional 120 min LC gradient scheme using samples from the PCZA cohort led to quantification of 3,800 proteins in both methods with high quantitative correlation (r = 0.77). MRMHR verification of 154 prioritized proteins showed high quantitative consistency with the 15 min SWATH data (r = 0.89). Separation of benign and malignant tissues achieved precision (AUC = 0.99). ECHS1 was further verified in a third cohort PCZD successfully, agreeing with RNAseq data from the TCGA in a different cohort (n=549). Our methods enables practical proteomic analysis of 204 tissue samples within 5 working days. CONCLUSION Single-shot, short gradient SWATH-MS coupled with MRMHR is both practical and effective in discovering and verifying protein biomarkers in clinical specimens.

Discovery and Multi-center Verification of Prostate Cancer Protein Biomarkers using Single-shot Short Gradient Microflow SWATH and MRMHR Mass Spectrometry